603229.SHG Zhejiang Ausun Pharmaceutical Co Ltd
- Market cap
- CNY 6.04B
- P/E
- -
- P/B
- 2.55x
- ROE
- 4.2%
- Dividend yield
- 1.50%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603229.SHG undervalued?
Graham numberThe Graham number of Zhejiang Ausun Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Ausun Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Ausun Pharmaceutical Co Ltd yet.
Zhejiang Ausun Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Ausun Pharmaceutical Co Ltd
Zhejiang Ausun Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical formulations, specialty active pharmaceutical ingredients (APIs), and pharmaceutical intermediates in China and internationally. The company offers products for liver diseases, respiratory system diseases, cardiovascular and cerebrovascular diseases, high-end fluorine products, prostaglandins, antibacterial agents, gout, anti-t…
Full company profileZhejiang Ausun Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Ausun Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 199M | 240M | 244M | 308M | 409M | 570M | 765M | 817M | 795M | 793M | 814M |
| Gross Profit | 109M | 141M | 106M | 151M | 227M | 308M | 392M | 444M | 422M | 424M | 409M |
| Operating Income | 62.6M | 60.3M | 47.2M | 61.1M | 96.6M | 160M | 258M | 291M | 241M | 139M | 142M |
| EBITDA | 74.5M | 87.6M | 43.7M | 66.9M | 134M | 182M | 240M | 285M | 248M | 220M | 106M |
| Net Income | 57.3M | 53.0M | 43.9M | 56.4M | 86.8M | 146M | 235M | 254M | 207M | 131M | 95.9M |
| EPS | 0.15 | 0.11 | 0.08 | 0.11 | 0.17 | 0.26 | 0.42 | 0.31 | 0.25 | 0.16 | 0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 446M | 742M | 802M | 886M | 1.38B | 1.84B | 2.32B | 2.95B | 2.98B | 3.09B | 2.88B |
| Total Liabilities | 203M | 177M | 204M | 241M | 255M | 585M | 854M | 810M | 710M | 816M | 596M |
| Shareholders' Equity | 243M | 565M | 598M | 645M | 1.13B | 1.25B | 1.46B | 2.14B | 2.27B | 2.27B | 2.29B |
| Cash & Short-term Investments | 110M | 240M | 279M | 342M | 739M | 675M | 613M | 1.12B | 1.10B | 1.22B | 951M |
| Total Debt | 60.6M | 62.5M | 72.0M | 45.0M | 41.0M | 110M | 242M | 302M | 271M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 93.2M | 46.8M | 11.5M | 87.7M | 138M | 174M | 121M | 222M | 178M | 157M | - |
| Capital Expenditure | 42.8M | 54.4M | 55.1M | 49.6M | 93.0M | 311M | 272M | 163M | 111M | 104M | 98.0M |
| Free Cash Flow | 50.4M | -7.58M | -43.6M | 38.1M | 45.5M | -137M | -151M | 58.4M | 66.6M | 52.1M | -22.8M |
| Ratios | |||||||||||
| ROE | 23.6% | 9.4% | 7.3% | 8.7% | 7.7% | 11.6% | 16.1% | 11.9% | 9.1% | 5.8% | 4.2% |
| ROA | 12.9% | 7.1% | 5.5% | 6.4% | 6.3% | 7.9% | 10.2% | 8.6% | 6.9% | 4.2% | 3.3% |
| Net Profit Margin | 28.8% | 22.1% | 18.0% | 18.3% | 21.2% | 25.6% | 30.8% | 31.1% | 26.0% | 16.5% | 11.8% |
| Debt to Equity | 0.25x | 0.11x | 0.12x | 0.07x | 0.04x | 0.09x | 0.17x | 0.14x | 0.12x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Ausun Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.50%
- Forward dividend
- 0.06 CNY
- Payout ratio
- 69.4%
- Ex-dividend date
- Jul 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 90.6M | 0.11 | 69.4% |
| 2024 | CNY 84.2M | 0.10 | 40.7% |
| 2023 | CNY 57.4M | 0.07 | 22.6% |
| 2022 | CNY 29.3M | 0.05 | 12.4% |
| 2021 | CNY 17.9M | 0.03 | 12.3% |
| 2020 | CNY 12.0M | 0.02 | 13.8% |
| 2019 | CNY 8.80M | 0.02 | 15.6% |
| 2018 | CNY 14.2M | 0.03 | 32.3% |
| 2017 | CNY 2.97M | 0.01 | 5.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jul 12, 2024.
Who owns Zhejiang Ausun Pharmaceutical Co Ltd
- Insiders 59.35%
- Institutions 2.37%
- Public & others 38.28%
- Shares outstanding 830M
- Free float 361M
Zhejiang Ausun Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Ausun Pharmaceutical Co Ltd
- Ticker
- 603229.SHG
- ISIN
- CNE100002XK2
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,328
- Fiscal year end
- December
- Address
- No. 5 Donghai Fourth Lane, Taizhou, China, 317016
- Phone
- 86 576 8558 9335
- Website
- ausunpharm.com
About Zhejiang Ausun Pharmaceutical Co Ltd
Zhejiang Ausun Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical formulations, specialty active pharmaceutical ingredients (APIs), and pharmaceutical intermediates in China and internationally. The company offers products for liver diseases, respiratory system diseases, cardiovascular and cerebrovascular diseases, high-end fluorine products, prostaglandins, antibacterial agents, gout, anti-tumor treatments, and nervous system disorders. It also provides customized contract research, development, and manufacturing services. In addition, the company engages in technology research and development, commissioned technology development, technology transfer, consulting, and promotion services; wholesale of organic intermediates; medical research and experimental development; market research; conference services; organization of exhibitions and displays; import and export trade of pharmaceuticals, food, cosmetics, medical devices, goods and technology, and related instruments and equipment; drug clinical trials; retail of pharmaceuticals; technical consultation and exchange; health consultation; and research and development of biochemical products. Zhejiang Ausun Pharmaceutical Co., Ltd. was incorporated in 2010 and is headquartered in Taizhou, China.
Zhejiang Ausun Pharmaceutical Co Ltd management
7- Mr. Zhiguo ZhengChairman & GM · born 1971
- Ms. Ding Min ZhuChief Financial Officer · born 1967
- Ms. Shilan ZhengAccounting Supervisor & Director · born 1975
- Mr. Huadong ZhangDeputy GM & Director · born 1977
- Mr. Xiaochen YingBoard Secretary · born 1981
- Mr. Kai GaoDeputy General Manager · born 1981
- Ms. Yu ZhongDeputy General Manager · born 1962